Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.78
$0.02(2.15%)
At close: 4:00 PM EDT
$0.78
$0.02(2.15%)
Day’s Range― - ―
52-Week Range$1.53 - $29.34
Previous Close$1.96
Volume1.77M
Average Volume (3M)158.19K
Market Cap
$20.56M
Enterprise Value$139.63M
Total Cash (Recent Filing)$47.14M
Total Debt (Recent Filing)$60.74M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 18, 2026EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding13,264,987
10 Day Avg. Volume196,125
30 Day Avg. Volume158,195
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)35.68
Price to Sales (P/S)0.00
P/FCF Ratio-3.71
Enterprise Value/Market Cap6.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$40.00Price Target Upside5028.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe randomized, sham-controlled REMAIN-1 result provides meaningful evidence that Revita may address a durable need after GLP-1 discontinuation. Demonstrated treatment separation, widening benefit over time, and dose-response findings could support product differentiation if longer-term endpoints and regulatory review remain favorable.
Safety ProfileA favorable safety and tolerability profile can improve adoption potential for a procedure-based therapy and support outpatient delivery through established endoscopy settings. Low observed serious-event burden also strengthens the product’s clinical narrative, although broader evidence remains necessary before commercialization.
Regulatory PositioningBreakthrough Device designation and constructive FDA feedback may help Fractyl maintain a defined regulatory pathway for Revita. The company also identifies a potential reimbursement route, so successful pivotal validation could convert clinical progress into a clearer launch strategy and commercial opportunity.
Bears Say
Pre-commercial LossesThe company has not yet established meaningful commercial revenue and continues to incur substantial losses while funding development. This limits internal funding capacity and leaves future earnings dependent on successful clinical progress, regulatory clearance, and eventual market adoption of its pipeline.
Cash Burn And Balance SheetHeavy recurring cash consumption and negative equity weaken financial flexibility during the remaining development period. Even with improved spending metrics, the company may need additional financing if milestones slip, costs rise, or commercialization takes longer, creating potential dilution or funding pressure.
Regulatory And Reimbursement RiskRevita’s commercial outlook remains contingent on FDA review of the complete pivotal safety dataset and on payer decisions about coverage and eligibility. Uncertain classification, approval timing, or reimbursement criteria could delay launch, narrow the addressable population, and reduce expected adoption.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $1.53 and its highest was $29.34 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $20.56M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 31 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Aug 10, 2026. The company reported -$1.92 earnings per share for the quarter, missing the consensus estimate of -$1.62 by -$0.3.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -1.49.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 13,264,987 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$1.92 in its last earnings report, missing expectations of -$1.62. Following the earnings report the stock price went up 3.963%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
GUTS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong clinical signals (robust 1-year randomized results, favorable safety, well-powered pivotal design) and concrete regulatory/reimbursement positioning, supported by cost discipline that extends runway into early 2027. Material risks remain—limited cash runway, ongoing operating losses, and outstanding regulatory and payer determinations—that depend on the upcoming pivotal 6-month readout and subsequent FDA review. On balance, positive clinical and strategic progress outweigh near-term financial and regulatory risks.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$40.00
▲(5028.21% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.62% Insiders
4.27% Mutual Funds
― Other Institutional Investors
85.36% Public Companies and Individual Investors